Loading patent…
OwnerSebastien Gallet, Pascal Berthelot +7inventors
InventorsSebastien Gallet, Pascal Berthelot, Nicolas Lebegue, Nathalie Flouquet, Pascal Carato, John Hickman, Alain Pierre, Bruno Pfeiffer, Pierre Renard
Estimating the term…
A compound of formula (I): wherein: represents benzo or pyrido, optionally fused in the 2-3, 3-4 or 4-5 position to a phenyl, (C4-C8)cycloalkyl or heterocyclic group, which may be optionally substituted, W represents X—Y or Y—X, wherein: X represents and Y represents oxygen or N—R3, n represents zero or an integer from 1 to 6, G, R1, R2 and R3 are as defined in the description, its enantiomers and diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base, and medicinal products containing the same which are useful for the treatment of cancerous diseases.
1-20. (canceled)
21- A compound selected from those of formula (I):
22- A compound of claim 21, wherein
23- A compound of claim 21, wherein
24- A compound of claim 21, wherein
25- A compound of claim 21, wherein
26- A compound of claim 21, wherein G represents aryl or heteroaryl, its enantiomers and diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base.
27- A compound of claim 26, wherein G represents phenyl substituted by one, two or three groups selected from linear or branched (C1-C6)alkoxy, benzyloxy and hydroxy, its enantiomers and diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base.
28- A compound of claim 21, wherein R3 represents linear or branched (C1-C6)alkyl, its enantiomers and diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base.
29- A compound of claim 21, wherein R3 represents hydrogen or linear or branched aryl(C1-C6)alkyl, its enantiomers and diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base.
30- A compound of claim 21, wherein
31- A compound of claim 30, wherein the substituents are located in the 3- or 4-position of the group
32- A compound of claim 21, wherein R1 and R2, which may be the same or different, each independently represent hydrogen, halogen, linear or branched (C1-C6)alkyl, linear or branched (C1-C6)alkoxy or linear or branched (C1-C6)trihaloalkyl, its enantiomers and diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base.
33- A compound of claim 21, which is 6-[(2-methoxyethoxy)methyl]-1-[2-(4-methoxyphenyl)ethyl]-1,6-dihydropyrido-[3,2-c][2,1,5]benzothiadiazepine-5,5-dioxide, and addition salts thereof with a pharmaceutically acceptable acid.
34- A compound of claim 21, which is 1-[2-(4-methoxyphenyl)ethyl]-1,6-dihydropyrido[3,2-c][2,1,5]benzothiadiazepine 5,5-dioxide, and addition salts thereof with a pharmaceutically acceptable acid.
35- A compound of claim 21, which is selected from:
36- A compound of claim 21, which is selected from:
37- A pharmaceutical composition useful for the treatment of cancerous diseases, comprising as active principle an effective amount of a compound of claim 21, together with one or more pharmaceutically acceptable excipients or vehicles.
38- A pharmaceutical composition useful for the treatment of leukaemia, adenocarcinoma and carcinoma, comprising as active principle an effective amount of a compound of claim 21, together with one or more pharmaceutically acceptable excipients or vehicles.
39- A method for treating a living animal body, including a human, afflicted with a condition associated with cancerous diseases comprising the step of administering to the living animal body, including a human, an amount of a compound of claim 21 which is effective for alleviation of the condition.
40- A method for treating an living animal body, including a human, afflicted with a condition associated with leukaemia, adenocarcinoma and carcinoma comprising the step of administering to the living animal body, including a human, an amount of a compound of claim 21, which is effective for alleviation of the condition.